2000

October 25, 2000 Flamel Technologies reports improved operating revenues and net income, reducing loss per share to $(0.04) for the third quarter

September 25, 2000 Flamel announces results of its Phase I study of once daily controlled release metformin

August 10, 2000 Flamel Technologies announces filing of Genvir™, a twice daily controlled release acyclovir for herpes treatment

August 9, 2000 Flamel appoints Stephen Willard as executive vice president, chief financial officer and general counsel

July 31, 2000 Technologies reports second quarter 2000 financial results

May 11, 2000 Flamel Technologies reports first quarter 2000 financial results

May 11, 2000 Flamel appoints Michael Myers executive vice president of sales, marketing and business development

April 18, 2000 Flamel’s Medusa drug delivery technology proves the principle of sustained release of human insulin

March 23, 2000 Flamel announces shareholder approval of $12.8 million private placement and election of three new board members

March 1, 2000 Flamel Technologies reports 1999 results

March 1, 2000 Flamel Technologies announces $12.8 Million private placement


1999

December 8, 1999 Flamel Technologies announces $42 million development and licensing agreement with Novo Nordisk for long-acting insulin

December 1, 1999 Flamel Technologies receives $1 million for development project

October 11, 1999 Flamel Technologies reports first product launch

October 4, 1999 Flamel Technologies to begin clinical study of Basulin

August 13, 1999 Monsanto and Flamel in collaboration discussions

July 28, 1999 Flamel Technologies reports second quarter 1999 results

June 8, 1999 Flamel appoints Janik Blouin general manager and board member

April 27, 1999 Flamel Technologies reports first quarter 1999 financial results

February 23, 1999 Flamel Technologies reports 1998 results

January 12, 1999 Flamel announces a long-term research & development agreement with Corning


1998

November 2, 1998 Flamel Technologies announces preliminary phase III data for Genvir in acute genital herpes

October 27, 1998 Flamel Technologies reports third quarter 1998 results - announces clinical trial completion for Genvir and progress with Asacard-

September 3, 1998 Flamel Technologies files for European approval for ASACARD™ cardiovascular aspirin launch of new clinical study to support product marketing campaign

July 28, 1998 Flamel Technologies reports second quarter 1998 results

May 8, 1998 Flamel Technologies submits a private financing plan to its shareholders

April 28, 1998 Flamel Technologies S.A. reports first quarter 1998 results

April 2, 1998 Basulin™ controlled-release insulin is the subject of a presentation at the 5th European Symposium on controlled drug delivery

March 17, 1998 Flamel Technologies reports 1997 financial results

February 2, 1998 Searle and Flamel Technologies annouce the UK Approval of ASACARD™ controlled release cardio vascular aspirin

January 16, 1998 Flamel Technologies S.A. announces a collaboration with Niro

January 6, 1998 Monsanto and Flamel Technologies to collaborate to improve agrochemical formulations


1997

December 23, 1997 Flamel Technologies S.A. names Barbara Sherrill chief financial officer

October 28, 1997 Flamel Technologies S.A. reports third quarter 1997 results

October 23, 1997 Flamel Technologies S.A announces initial clinical results on its Asacard cardiovascular aspirin

July 31, 1997 Flamel Technologies S.A. reports second quarter 1997 results

May 12, 1997 Flamel Technologies S.A. reports first quarter 1997 results

May 5, 1997 Flamel Technologies S.A. files IND in U.S. for ASACARD

March 27, 1997 Flamel Technologies S.A. names Dr. Philippe Vivet vice president and director of medical affairs

March 26, 1997 Flamel Technologies S.A. reports fourth quarter 1996 results

February 24, 1997 Flamel Technologies S.A. and SmithKline Beecham to terminate collaboration in vaccine delivery

January 30, 1997 Flamel Technologies S.A.commences phase III clinical trial of controlled-released aciclovir for treatment of genital herpes


1996

December 2, 1996 Flamel Technologies S.A. signs definitive agreement to acquire french pharmaceutical production facility